X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (97) 97
index medicus (78) 78
female (55) 55
hypercholesterolemia (54) 54
male (54) 54
middle aged (49) 49
cardiac & cardiovascular systems (48) 48
cardiovascular (48) 48
cholesterol (41) 41
statins (39) 39
cholesterol, ldl - blood (36) 36
double-blind method (36) 36
ezetimibe (36) 36
aged (34) 34
risk factors (33) 33
anticholesteremic agents - therapeutic use (32) 32
drug therapy, combination (32) 32
treatment outcome (32) 32
density-lipoprotein cholesterol (29) 29
hypercholesterolemia - drug therapy (29) 29
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (28) 28
care and treatment (27) 27
low density lipoproteins (27) 27
safety (27) 27
atorvastatin (26) 26
cardiovascular disease (26) 26
lipids (26) 26
adult (24) 24
pcsk9 (24) 24
hyperlipidemias - drug therapy (23) 23
simvastatin (23) 23
drug therapy (22) 22
hypolipidemic agents - therapeutic use (21) 21
internal medicine (21) 21
peripheral vascular disease (21) 21
efficacy (20) 20
simvastatin - therapeutic use (20) 20
alirocumab (19) 19
azetidines - therapeutic use (19) 19
cardiovascular diseases - prevention & control (18) 18
ldl-c (18) 18
therapy (18) 18
atherosclerosis (17) 17
cardiovascular diseases (17) 17
fenofibrate - therapeutic use (17) 17
pharmacology & pharmacy (17) 17
heterozygous familial hypercholesterolemia (16) 16
hypercholesterolemia - blood (16) 16
medicine, general & internal (16) 16
monoclonal-antibody (16) 16
cardiology and cardiovascular medicine (15) 15
low density lipoprotein (15) 15
cardiology (14) 14
cholesterol, hdl - blood (14) 14
diabetes (14) 14
familial hypercholesterolemia (14) 14
ldl cholesterol (14) 14
statin therapy (14) 14
cardiovascular-disease (13) 13
hyperlipoproteinemia type ii - drug therapy (13) 13
management (13) 13
statin (13) 13
triglycerides (13) 13
triglycerides - blood (13) 13
anticholesteremic agents - adverse effects (12) 12
apolipoproteins b - blood (12) 12
azetidines - administration & dosage (12) 12
cardiovascular diseases - etiology (12) 12
coronary-heart-disease (12) 12
fenofibrate (12) 12
health aspects (12) 12
lipids - blood (12) 12
risk (12) 12
analysis (11) 11
anticholesteremic agents - administration & dosage (11) 11
dosage and administration (11) 11
drug combinations (11) 11
dyslipidemia (11) 11
fenofibrate - administration & dosage (11) 11
genetic aspects (11) 11
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (11) 11
hypolipidemic agents - administration & dosage (11) 11
life sciences (11) 11
monoclonal antibodies (11) 11
pravastatin (11) 11
antibodies, monoclonal - therapeutic use (10) 10
azetidines - adverse effects (10) 10
combination therapy (10) 10
coronary-artery-disease (10) 10
dyslipidemias - drug therapy (10) 10
fenofibrate - adverse effects (10) 10
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (10) 10
hypolipidemic agents - adverse effects (10) 10
ldl-cholesterol (10) 10
research (10) 10
rosuvastatin (10) 10
time factors (10) 10
adolescent (9) 9
biochemistry & molecular biology (9) 9
biomarkers - blood (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 16, pp. 1489 - 1499
Journal Article
Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 12/2015, Volume 13, Issue 12, pp. 1307 - 1323
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipoprotein metabolism, mainly by modulating LDL receptor activity. Alirocumab... 
LDL-cholesterol | cardiovascular disease | alirocumab | PCSK9 | hypercholesterolemia | Cardiovascular disease | Hypercholesterolemia | Alirocumab
Journal Article
Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 12/2017, Volume 15, Issue 12, pp. 923 - 932
Introduction: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved... 
cardiovascular prevention | LDL-cholesterol | PCSK9 | Alirocumab | hypercholesterolemia | Cardiovascular prevention | Hypercholesterolemia
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 01/2014, Volume 13, Issue 1, p. 26
Journal Article
La Presse Médicale, ISSN 0755-4982, 09/2018, Volume 47, Issue 9, pp. 769 - 774
Il est recommandé d’évaluer le risque cardiovasculaire en prévention primaire au-delà de 40 ans à l’aide de l’outil SCORE, hormis pour les patients... 
Journal Article
Presse Medicale, ISSN 0755-4982, 09/2018, Volume 47, Issue 9, pp. 769 - 774
Total cardiovascular risk estimation using a system such as SCORE is recommended for adults > 40 years of age without evidence of cardiovascular disease,... 
Journal Article
Current Opinion in Lipidology, ISSN 0957-9672, 06/2013, Volume 24, Issue 3, pp. 251 - 258
Purpose of review To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal... 
Monoclonal antibodies | LDL-cholesterol | Proprotein convertase subtilisin kexin type 9 | LDL receptor pathway | Familial hypercholesterolemia | NONHUMAN-PRIMATES | proprotein convertase subtilisin kexin type 9 | AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA | BIOCHEMISTRY & MOLECULAR BIOLOGY | SUBTILISIN/KEXIN TYPE 9 | MONOCLONAL-ANTIBODY | LDL CHOLESTEROL | DENSITY-LIPOPROTEIN CHOLESTEROL | PLASMA-CHOLESTEROL | familial hypercholesterolemia | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | THERAPEUTIC TARGET | ENDOCRINOLOGY & METABOLISM | PERIPHERAL VASCULAR DISEASE | LOWERING TREATMENT | monoclonal antibodies | Proprotein Convertases - antagonists & inhibitors | Receptors, LDL - genetics | Gene Expression | Humans | Proprotein Convertases - metabolism | Receptors, LDL - antagonists & inhibitors | Cholesterol, LDL - antagonists & inhibitors | Receptors, LDL - metabolism | Antibodies, Monoclonal - therapeutic use | Clinical Trials as Topic | Proprotein Convertases - genetics | Hyperlipoproteinemia Type II - metabolism | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipid Metabolism - drug effects | Serine Endopeptidases - genetics | Cholesterol, LDL - metabolism | Protein Binding | Serine Endopeptidases - metabolism | Hyperlipoproteinemia Type II - drug therapy | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Proprotein Convertase 9
Journal Article
Archives of Cardiovascular Diseases, ISSN 1875-2136, 2013, Volume 107, Issue 1, pp. 58 - 66
Journal Article
Cardiovascular Diabetology, 06/2019, Volume 18, Issue 1, pp. 1 - 20
Journal Article
Journal Article
Expert review of cardiovascular therapy, 11/2017, p. 1
Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the... 
Journal Article